The effect of latanoprost for the treatment of patient with scalp patchy alopecia

Evaluation of clinical efficacy of latanoprost drop 0.005% for the treatment of patients with scalp patchy alopecia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090813002342N11

Enrollment

Registered

2020-10-07

Start date

2018-06-11

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata. Alopecia areata

Interventions

Intervention 1: Intervention group: Patients in this group received latanoprost drop 0.005% at a rate of 5 drops per 3 cm2 baldness (twice daily) with clobetasol in isopropyl alcohol (twice daily). L

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with scalp patchy alopecia Minimum age 12 years

Exclusion criteria

Exclusion criteria: Pregnancy Liver disease Kidney disease Diabetes Autoimmune diseases Use of immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
Hair loss area. Timepoint: At the beginning of the study, the end of the first, second and third months. Method of measurement: Hair loss site photo.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Rafati

Mazandaran University of Medical Sciences

mrrafati@mazums.ac.ir+98 11 3354 3084

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026